FierceBiotech2h
Boston Scientific clocks over $1B in Farapulse revenue for the afib therapy’s first year
Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...
Ultragenyx reports positive data on gene therapy for rare disease
NOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ: NASDAQ:RARE), a $4.08 billion market cap biotechnology company with 27% revenue growth in the past year, today unveiled new data indicating ...
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business
FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.
Yahoo Finance28d
Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue
Such preliminary revenue results for full year 2024 are ... and cell and gene therapy companies. Forward-Looking Statements This press release contains, and our officers and representatives ...
BioSpace1d
Regeneron Misses on Eylea, Dupixent Sales; Issues First-Ever Dividends
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
Baxter Kidney Care is Now Vantive, A New Standalone Vital Organ Therapy Company
Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with ...
Seeking Alpha20d
Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy
They had $26 million in collaboration revenue offset by $59.6 million ... may be on the fast track to an approval. Granted, cell therapy companies have shown historically that there is upside ...